Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants

Completed · Phase 4

Conditions studied: Blood Loss, Surgical

In brief

The objective of this study is to assess the safety and immunogenicity of recombinant thrombin (rThrombin) administered as an aid to hemostasis during burn wound excision and skin grafting in pediatric patients, newborn through 17 years of age.

Key facts

Study ID

NCT00859547

Run by

ZymoGenetics

People needed

30

Starts

2009-03-01

Expected to finish

2010-01-01

Last updated by the study team

2012-01-26

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of newborn through 17 years at time of enrollment
• At least 1 skin graft recipient site measuring at least 1% of total body surface area (TBSA)
• Total initial burn wounds estimated to measure less than 40% of TBSA
• Bleeding indicating treatment with rThrombin during the surgical procedure
• Females of child-bearing potential must have a negative urine or serum pregnancy test within 2 days prior to study-drug treatment
• informed consent document signed by legal representative (guardian) and approved by an institutional review board/independent ethics committee (IRB/IEC)
• Participant has signed an IRB/IEC-approved pediatric assent document, if applicable

You may not qualify if…

• Gestational age younger than 36 weeks at birth (for infants younger than 2 years)
• Documented active infection at the graft recipient site (participants with resolved infections at potential graft recipient sites are not excluded)
• Acute inhalation injury, as defined by bronchoscopic evidence of lower airway injury
• Currently undergoing autologous skin grafting for ischemic ulcer disease or cutaneous malignancies
• Presence of antibodies or hypersensitivity to the study drug or any of its components, other thrombin preparations, or coagulation factors
• Transfusion of whole blood, fresh frozen plasma, cryoprecipitate, or platelets within 24 hours prior to study-drug treatment (packed red blood cell transfusions are allowed)
• History of HIV infection or other immunodeficiency syndrome or is taking immunosuppressive or antirejection medications
• Medical, social, or psychosocial factors that, in the opinion of the investigator, could affect safety or compliance with study procedures
• Breastfeeding or being breastfed
• Treatment with any experimental agent within 30 days of study enrollment or treatment

Where it is running

• Arizona Burn Center — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.